Shanghai Wibson Biotechnology: difference between revisions
Diff·revision 26 → 27·22:24, 10 May 2025
Difference between revision 26 and revision 27 of Shanghai Wibson Biotechnology. 9 lines changed; the page grew by 339 bytes.
| Revision 26 — 12:46, 6 May 2025 BiliaryBea (talk) cite the trial publication rather than the press release 6,247 bytes ±0 | Revision 27 — 22:24, 10 May 2025 ScopeSeverin (talk) move table to the section it supports 6,586 bytes +339 | ||
|---|---|---|---|
| 47 | | Injectable oils and raw materials | Bulk | Certificate, limited detail | | 47 | | Injectable oils and raw materials | Bulk | Certificate, limited detail | |
| 48 | 48 | ||
| + | 49 | The catalogue is broadly the sector standard and does not distinguish the organisation from its comparators, which is itself a relevant fact for a reader trying to tell them apart.{{r|selfpub}} | |
| + | 50 | ||
| 49 | == References == | 51 | == References == |
| 50 | {{reflist}} | 52 | {{reflist}} |
| ⋮ | ⋮ | ||
| 55 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 57 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| 56 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 58 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| + | 59 | ||
| + | 60 | == See also == | |
| + | 61 | * [[Certificate of analysis]] | |
| + | 62 | * [[Third-party testing]] | |
| + | 63 | * [[Area percent purity]] | |
| + | 64 | * [[Peptide content]] | |
| + | 65 | * [[Research use only]] | |
| 57 | 66 | ||
| 58 | {{DEFAULTSORT:Shanghai Wibson Biotechnology}} | 67 | {{DEFAULTSORT:Shanghai Wibson Biotechnology}} |